Next 10 |
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Palisade Bio (PALI), formed by the reverse merger of Seneca BioSciences (SNCA) and privately held Leading BioSciences, will begin trading on the Nasdaq today.A concurrent $20M investment was led by Altium Capital as part of the merger.Palisades is focusing on drugs for gastrointestinal condit...
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc. - Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021 - New combined company, Palisades Bio, expected to begin trading on Nasdaq Capital...
CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA), subject to certain conditions to...
Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of April 19, 2021, based on voting indications, Proposal 1 is expected to be approved...
Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca stockholders who voted at the virtual Special Meeting on April 9, 2021. CARL...
Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021 Five of six proposals related to merger transaction with Leading BioSciences were approved by Seneca stockholders at the Special Meeti...
Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
News, Short Squeeze, Breakout and More Instantly...
Neuralstem Inc. Company Name:
SNCA Stock Symbol:
NASDAQ Market:
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc. - Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021 - New combined company, Palisades Bio, expected to begin trading on Nasdaq Capital...